Dear Editor,Coronavirus disease 2019(COVID-19)is a highly infectious respiratory disease that continues to pose a serious global public health emergency.The disease shows a high infection rate,long incubation period,a...Dear Editor,Coronavirus disease 2019(COVID-19)is a highly infectious respiratory disease that continues to pose a serious global public health emergency.The disease shows a high infection rate,long incubation period,and rapidly emerging variants,which have led to its rapid spread worldwide(Krammer 2020).Many vaccines have been developed for the control of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),the virus responsible for COVID-19,including vaccines based on messenger RNA(mRNA)(Polack et al.2020),viral vectors(Zhu et al.2020),recombinant proteins(Yang et al.2020),and inactivated SARS-CoV-2(Zhang et al.2021).展开更多
Dear editor,The 2019 novel coronavirus(later renamed as SARS-CoV-2 in February 2020)infected over 12 million people globally by early July 2020,causing mild to severe COVID-19 in millions.Monitoring the levels of anti...Dear editor,The 2019 novel coronavirus(later renamed as SARS-CoV-2 in February 2020)infected over 12 million people globally by early July 2020,causing mild to severe COVID-19 in millions.Monitoring the levels of antibodies such as immunoglobin(Ig)G,M and A that are specific to SARS-CoV-2 and present in the blood provides not only an alternative method for diagnosing SARS-CoV-2 infection(including asymptomatic carriers),but also a simple way to monitor immune responses in convalescent patients or after vaccination.A high and persistent level of antibodies specific to SARS-CoV-2,especially those that can bind to and neutralize the virus,would be a strong indication that an immunized host could resist to SRAS-CoV-2 infection.Currently,there are no effective drugs to specifically prevent or cure SARS-CoV-2 infection;therefore,host immune responses and antibody-based therapeutics will continue to play important roles in combating and later preventing COVID-19.展开更多
Dear Editor,The spread of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)led to a global pandemic with 260 million infected people.A variety of vaccines,including the mRNA and recombinant vaccines,were dev...Dear Editor,The spread of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)led to a global pandemic with 260 million infected people.A variety of vaccines,including the mRNA and recombinant vaccines,were developed to prevent the spread of the disease.1,2 There is an urgent need for testing the vaccine-induced long-term memory response based on the immunological principles and identifying the optimal combination of dose and injection manner to provide important information for clinical application.展开更多
Dear Editor,The coronavirus disease 2019(COVID-19),caused by the Severe Acute Respiratory Syndrome Coronavirus 2(SARS-CoV-2),is an ongoing threat to public health.Due to the presence of neutralizing antibodies in conv...Dear Editor,The coronavirus disease 2019(COVID-19),caused by the Severe Acute Respiratory Syndrome Coronavirus 2(SARS-CoV-2),is an ongoing threat to public health.Due to the presence of neutralizing antibodies in convalescent patients,convalescent plasma transfusion has been tested as a promising therapy for severe COVID-19 patients.12 We and others previously found a surprisingly early serum lgA antibody response in the COVID-19 patients.However,the relative contribution of the lgA antibody towards virus neutralization with respect to other antibody isotypes is unknown.展开更多
基金supported by Strategic Priority Research Program of the Chinese Academy of Sciences(XDB39000000 to T.X.)National Natural Science Foundation of China(81925009 to T.X.,81790644 to T.X.,81900855 to M.Z.,82000941 to D.T.)+3 种基金Jack Ma Foundation(2019-nCoV)CAS Project for Young Scientists in Basic Research(YSBR-013)Fundamental Research Funds for the Central Universities(WK5290000001 to Y.C.,WK5290000002 to Y.Y.,WK2090050048 to M.Z.,WK2070000174 to M.Z.)supported by the Anhui Provincial Natural Science Foundation(1808085MH289 to M.Z.).Joint Laboratory of Innovation in Life Sciences from the University of Science and Technology of China(USTC)and Changchun Zhuoyi Biological Co.Ltd.
文摘Dear Editor,Coronavirus disease 2019(COVID-19)is a highly infectious respiratory disease that continues to pose a serious global public health emergency.The disease shows a high infection rate,long incubation period,and rapidly emerging variants,which have led to its rapid spread worldwide(Krammer 2020).Many vaccines have been developed for the control of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),the virus responsible for COVID-19,including vaccines based on messenger RNA(mRNA)(Polack et al.2020),viral vectors(Zhu et al.2020),recombinant proteins(Yang et al.2020),and inactivated SARS-CoV-2(Zhang et al.2021).
基金T.J.is supported by the Strategic Priority Research Program of the Chinese Academy of Sciences(XDB29030104)National Natural Science Foundation of China(31870731 and U1732109)+3 种基金the Fundamental Research Funds for the Central Universities(WK2070000108)a COVID-19 special task grant supported by Chinese Academy of Sciences Clinical Research Hospital(Hefei)with Grant No.YD2070002017M.H.is supported by the new medical science fund of University of Science and Technology of China(WK2070000130)J.W.and X.Y.are supported by the Fundamental Research Funds for the Central Universities with Grant Nos.YD9110004001 and YD9110002002,respectively.
文摘Dear editor,The 2019 novel coronavirus(later renamed as SARS-CoV-2 in February 2020)infected over 12 million people globally by early July 2020,causing mild to severe COVID-19 in millions.Monitoring the levels of antibodies such as immunoglobin(Ig)G,M and A that are specific to SARS-CoV-2 and present in the blood provides not only an alternative method for diagnosing SARS-CoV-2 infection(including asymptomatic carriers),but also a simple way to monitor immune responses in convalescent patients or after vaccination.A high and persistent level of antibodies specific to SARS-CoV-2,especially those that can bind to and neutralize the virus,would be a strong indication that an immunized host could resist to SRAS-CoV-2 infection.Currently,there are no effective drugs to specifically prevent or cure SARS-CoV-2 infection;therefore,host immune responses and antibody-based therapeutics will continue to play important roles in combating and later preventing COVID-19.
基金the National Natural Science Foundation of China(Grant 81974258,31870731,and 31971129)the Strategic Priority Research Program of the Chinese Academy of Sciences(Grant No.XDB29030104)the Fundamental Research Fund for the Central Universities(WK3520000011,WK9110000092,and EF2060030006).
文摘Dear Editor,The spread of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)led to a global pandemic with 260 million infected people.A variety of vaccines,including the mRNA and recombinant vaccines,were developed to prevent the spread of the disease.1,2 There is an urgent need for testing the vaccine-induced long-term memory response based on the immunological principles and identifying the optimal combination of dose and injection manner to provide important information for clinical application.
基金This work was supported by grants from the Strategic Priority Research Program of the Chinese Academy of Sciences(XDB29030104)National Natural Science Fund(31870731,31971129 and U1732109)the Fundamental Research Funds for the Central Universities,the new medical science fund of USTC,COVID-19 special task grants supported by Chinese Academy of Science Clinical Research Hospital(Hefei)with Grant Nos.YD2070002017 and YD2070002001,respectively.
文摘Dear Editor,The coronavirus disease 2019(COVID-19),caused by the Severe Acute Respiratory Syndrome Coronavirus 2(SARS-CoV-2),is an ongoing threat to public health.Due to the presence of neutralizing antibodies in convalescent patients,convalescent plasma transfusion has been tested as a promising therapy for severe COVID-19 patients.12 We and others previously found a surprisingly early serum lgA antibody response in the COVID-19 patients.However,the relative contribution of the lgA antibody towards virus neutralization with respect to other antibody isotypes is unknown.
